Bart Dzikowski is a Managing Director at the Novartis Venture Fund and its Head of Transactions & Legal based in Basel, Switzerland. He currently serves on the boards of Enterprise Therapeutics Holdings, Amphista Therapeutics and UZH Life Sciences Fund and was previously on the boards of Oculis (until its NASDAQ IPO) and Inflazome (until its sale to Roche). Prior to joining NVF, Bart held various senior roles in Novartis’ Corporate Legal M&A and BD&L groups. Before joining Novartis in 2009, Bart was a Vice President with the Investment Banking Division of Bank of America/Merrill Lynch in New York and, before that, he was an attorney with the Corporate/M&A Group at the law firm of Allen & Overy LLP in New York. Bart holds Juris Doctor and Bachelor of Laws degrees from McGill Law School in Canada and is a member of the New York State Bar.